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Abstract
Our gut microbiota is involved in human development, nutrition, and the
pathogenesis of gut disorders, but has more recently been implicated as a possible
mechanism in the pathophysiology of several brain disorders, including disorders of mood
and affect, such as depression. Researchers have referred to this dynamic, bidirectional
signaling pathway between the gut and the brain as the “gut-brain axis.” However, most
research on this axis has been limited to rodent studies, and there has been little insight into
the mechanism behind it. I propose that the kynurenine pathway, where tryptophan is
converted to kynurenine, is a compelling mechanism mediating the gut microbiota’s
influence on depression. Kynurenine is a metabolite associated with depression, and this
pathway has been shown to be manipulated through probiotic (Lactobacillus reuteri)
consumption. I propose to study a probiotic intervention in humans, which would assess
tryptophan metabolism along the kynurenine pathway by measuring metabolites downstream
of this pathway. Urine, feces and blood samples would be collected from two groups, control
and probiotic treatment, on day zero and day thirty. Colonic biopsies would be obtained on
day thirty, and various analyses would be run to measure metabolite concentrations from the
collected samples. The results from this study will help clarify a mechanistic connection
between gut microbes and depression via the kynurenine pathway. Additionally, findings
could indicate that a probiotic intervention has the ability to influence depressive behavior
via a two-pronged approach originating from the kynurenine pathway.
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Introduction
Depression and the Importance of our Gut Microbes
Our gastrointestinal tract is home to over 1 x 1014 microorganisms that are
responsible for many functions throughout our body and essential for health (1). It has been
estimated that at least 1 x 104 distinct species cohabit the human gut and compose the
microbiota, an ecological community of commensal, mutualistic and pathogenic
microorganisms (2). This provides a glimpse into the size and complexity of the human
microbiome, and the important role our gut microbiota plays in our health. Our gut
microbiota is involved in the pathogenesis of gut disorders, but has more recently been
implicated as a possible mechanism in the pathophysiology of several brain disorders,
including disorders of mood and affect (3). There is growing evidence of bidirectional,
reciprocal communication between the gut and brain (1, 3, 4) that has important implications
in human health. Researchers have referred to this dynamic, bidirectional signaling pathway
as the “gut-brain axis,” and components of this axis have, and are currently receiving
extensive study as dysfunction of this axis has broad pathophysiological consequences (1).
Several experimental approaches have been used to study the effect of gut microbiota on gutbrain interactions, including gut microbial manipulation with probiotics, prebiotics, and
antibiotics, fecal microbial transplantation and germ-free animal models (3). While there are
many limitations of these approaches, there has been significant progress towards better
understanding the role our gut microbiota plays in CNS disorders.
Depression is a mood disorder that is frequently studied in this axis, with the hope to
further clarify its link to the gut. Several studies in mice have demonstrated that there is a
distinct difference in the composition of gut microbiota in animal models of depression and
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chronic stress (5). In addition, the high co-morbidity between psychiatric symptoms, such as
depression or anxiety, with gastrointestinal disorders including irritable bowel syndrome
(IBS) and inflammatory bowel disorder (IBD) is further evidence of the importance of this
axis (6). Further clarifying the microbiome’s link to depression is important, as depression is
considered the leading cause of disability worldwide, impacting more than 350 million
people (7). In addition, according to the World Health Organization, depression will displace
heart disease in terms of cost of caring for patients by the year 2020 (7). Serotonin-specific
reuptake inhibitor medications (SSRIs) are the primary medications prescribed for patients
who are diagnosed with depression, however, these medications do not treat the root cause of
depression, and instead only improve symptoms. With this in mind, it is interesting to note
that antidepressants are one of the three most commonly used therapeutic drug classes in the
U.S. (8). This common use of antidepressants is alarming, because the cause of depression is
not entirely understood, and these antidepressants are only aiding in symptom relief, rather
than curing the problem (2). SSRIs block the reabsorption of serotonin in the brain, making
more serotonin available, however, this same neurotransmitter found in the brain is primarily
produced in the gut (2). In fact, more than 90% of the body’s serotonin is synthesized in the
gut (9). Ultimately, a further understanding of the connection between the gut and depression
could prove to have important implications in the medical field, and potentially reduce
antidepressant use among U.S. society.
One of the major recent findings in this field was from an experiment led by Irish
scientist John Cryan in 2011. His research group fed half their mice with Lactobacillus
rhamnosus (JB-1), a lactic acid bacterium shown to be beneficial for the gut and commonly
present in probiotics, then evaluated several different measures of behavior between the two
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groups of mice, such as tests for anxiety and depression-related behavior, and stress-induced
corticosterone levels (10). They found that the mice given L. rhamnosus kept swimming for
longer and with more motivation in the forced swim test analysis, which is a test for
depression-related behavior (10). In addition, these mice were also found to have lower
stress-induced corticosterone levels, showing that L. rhamnosus had beneficial effects on the
mouse (10). Yet when they severed the mouse’s vagus nerve, there was no difference
recorded between the two groups of mice, thus the vagus nerve plays a critical role in
communication between the gut and the brain (10). Overall, this study highlights the
important role of bacteria in the bidirectional communication of the gut-brain axis and
suggests that certain organisms may prove to be useful therapeutically in stress-related
disorders such as anxiety and depression. One of the first human studies assessing the
psychotropic-like effects of probiotics was also in 2011 by a group of researchers led by
Messaoudi. The clinical study demonstrated that in the general population, when a probiotic
formulation (PF) of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 was
taken in combination for 30 days, global scores of hospital anxiety and depression scale
decreased (11). Thus oral intake of this PF showed beneficial effects on anxiety and
depression related behaviors in human volunteers, just like it did in the mice. Mouse studies
have begun to elucidate a link between gut microbiota and depression, and clinical trials,
such as Messaoudi et al.’s, are working to translate these findings from mouse studies to the
human body. These studies suggest a potential for positive effects of some probiotics on
mood, however, there is a need for larger clinical trials, with biological and self-reported
outcomes in patient populations, in order to make clear conclusions on a mechanistic
connection between the gut microbiota and the brain (12). Deciphering the mechanism by
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which microbiota communicate with the gut-brain axis will be crucially important for the
development of any microbiota-based and microbiota-specific therapeutic strategies for CNS
diseases and mood disorders.
The gut is composed of a variety of different bacterial phyla, such as Firmicutes
(genera such as Lactobacillus, Clostridium, Enterococcus) and Bacteroidetes (genera such as
Bacteroides), which account for the majority (13). Other phyla are also present in the gut
such as Actinobacteria (Bifidobacteria), Proteobacteria (Escherichia coli), Fusobacteria,
Verrucomicrobia and Cyanobacteria (13). Not all genera of microbes are considered
beneficial to mental health, and some are more than others, so it is important for future
research to focus on deciphering which genera or species of bacteria are more beneficial than
others, and what they specifically do that proves to be beneficial. Lactobacillus and
Bifidobacterium are the main genera showing beneficial effects on mood disorders, such as
anxiety and depression (12). B. infantis has been shown to increase plasma tryptophan levels,
L. helveticus was shown to prevent diet-induced anxiety-like behavior and memory, and B.
longum NCC3001 reversed colitis-induced anxiety in the mouse via the vagus nerve (5).
These results have not been replicated in humans. Clinical validation of these findings is
necessary in order to determine whether or not probiotics can be used therapeutically in
mood disorders. In conclusion, findings from mouse studies begin to give a greater glimpse
into the powerful role our gut plays in depression.
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The Immune System: Mediator of Communication between the Gut and the Brain
The digestive tract does not operate independently, but instead requires functional
integration with other organ systems. Communication between the gastrointestinal tract and
the central nervous system (CNS) and enteric nervous system (ENS) are examples of how
signals originating in one of these organ systems affect the function of the other (14). The
ENS is a complex network of neurons that can function independently of the CNS, control
gut motility and local blood flow, and directly communicate with cells of the intestinal
barrier (14). However, mechanisms by which the ENS integrates with microbe-mediated GI
immune responses are still poorly understood. For example, it is largely unknown whether
the ENS senses the microbial environment and initiates an immune response, or whether the
ENS senses immune responses and then modifies or propagates those signals (15).
Microbial regulation of tryptophan, serotonin and kynurenine metabolism has become
a focal point in understanding the influence exerted by the gut microbiota on brain function
and behavior. The kynurenine pathway, where tryptophan is converted to kynurenine (Figure
1), is of particular interest because kynurenine pathway metabolism might be regulated by
microbial control of neuroendocrine function and parts of the immune system (16). Changes
in the supply and availability of tryptophan has many implications for ENS and CNS
functioning and consequently gut-brain axis signaling.
Tryptophan is an essential amino acid, so it must be supplied from one’s diet (17).
Some common sources of tryptophan are bananas, dried prunes, milk, peanuts, chocolate and
white meats, such as chicken, turkey and tuna (17). The gut microbiota can also directly
utilize tryptophan, which could potentially limit its availability to the host (18). Additionally,
B. subtilis is a known producer of tryptophan, a precursor to serotonin, so there are bacterial
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strains that have the ability to directly influence tryptophan levels and indirectly influence
serotonin levels (19). Thus, bacterial tryptophan utilization, tryptophan synthesis and dietary
supply of this essential amino acid, all play a role in the tryptophan level in the gut and
circulating tryptophan availability for the individual.

Figure 1. The kynurenine pathway, where tryptophan is either converted to kynurenine or
serotonin.
While tryptophan is the precursor molecule to serotonin, around 90% of tryptophan is
metabolized to kynurenine or the other downstream metabolites, kynurenic acid and
quinolinic acid (Figure 1) (16). The rate of tryptophan metabolism along the kynurenine
pathway is dependent on expression of indoleamine-2,3-dioxygenase (IDO1), and IDO1
expression can be induced by the action of inflammatory cytokines such as Interferon (IFN)γ (16). As IDO1 is induced by proinflammatory cytokines, its expression has been proposed
as a biomarker of GI diseases, including inflammatory bowel disease and colon cancer (16).
Additionally, there are two interleukins, IL-10 and IL-4, that influence tryptophan
metabolism down the kynurenine pathway and interact directly with IFNγ (20). Regulatory T
cells produce IL-10, which directly inhibit TH1 cells that produce IFNγ (Figure 2) (20). IL-4,
produced by TH2 cells, directly inhibits IFNγ, and conversely, IFNγ inhibits IL-4 (Figure 2)
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(20). Thus IL-10 and IL-4 both inhibit tryptophan metabolism down the kynurenine pathway,
and instead drive the pathway towards serotonin production (Figure 2).

Figure 2. Immune system components involved in the kynurenine pathway. Adapted from
reference 20.
IDO1, the enzyme that converts tryptophan to kynurenine, was shown to be inhibited
by Lactobacillus in a mice study conducted by Valladares et al. in 2013. Valladares et al.
found that feeding L. johnsonii to rats increased H2O2 concentrations in the ileal lumen, and
correlated with decreased peripheral kynurenine concentrations and altered IDO distribution
(21). Most importantly, L. johnsonii was found to produce reactive oxygen species (ROS),
H2O2, that inhibits the expression of the metabolizing enzyme, IDO1, in the intestine (21).
Valladares et al. found that this decreased IDO activity in the gut consequently reduced
peripheral kynurenine levels and increased ileum and peripheral serotonin levels (21). These
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findings are supported by another mice study conducted by Marin et al. in 2017. Marin et al.
used L. reuteri instead of L. johnsonii for their probiotic feeding in mice, because L. reuteri
has been shown to colonize several vertebrate hosts, and was shown to improve despair and
anxiety-like behaviors in mice (22). Their results show increased ido1 expression in the
intestines after stress, which is decreased after L. reuteri treatment (22). Marin et al. found
that chronic stress significantly altered intestinal microbiota composition, primarily by
decreasing the abundance of Lactobacillus. In addition, they observed increased circulating
kynurenine levels in stressed mice (22). Ultimately, Marin et al. found that treatment with L.
reuteri alleviates despair behavior by directly inhibiting intestinal ido1 expression and
decreasing the circulating level of kynurenine, which is a metabolite associated with
depression (23).
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Figure 3. The kynurenine pathway & the link to inflammation and the gut-brain axis. Image
of the brain adapted from reference 24.
The kynurenine pathway appears to be a compelling mechanism mediating the gut
microbiota’s influence on the brain (Figure 3). Our gut microbes, specifically Lactobacillus,
are involved in the mechanism by producing H2O2 that directly inhibits IDO1, the enzyme
that converts tryptophan to kynurenine. Because kynurenine has been associated with
depression, this pathway connects to the brain (23). More specifically, kynurenine can
readily cross the blood-brain barrier to drive depression in the CNS by disrupting
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neurotransmitter balance and driving neuroinflammation (25, 26). Thus, disruptions in
tryptophan-kynurenine metabolism are an important factor in mediating despair behavior
(22). The downstream metabolites of kynurenine, kynurenic acid and quinolinic acid, cross
the blood-brain barrier very poorly and must be formed locally within the brain (25, 27).
Quinolinic acid has been found to promote local inflammation within the CNS and modulate
neuronal excitability, thus it can influence the brain in alternate ways (28). Kynurenic acid is
protective against this neuronal excitotoxic action of quinolinic acid, and is considered
neuroprotective (29). Thus, the downstream metabolites of kynurenine are not directly
associated with depression, however, they influence the body in different ways that are both
beneficial and harmful. Another important aspect of the kynurenine pathway is that IDO can
also catalyze the conversion of 5-HT (serotonin) to 5-hydroxykynuramine, meaning
increased IDO activity has been correlated with increased serotonin turnover (21). This is an
important consideration, as lower IDO activity alone could result in both decreased
kynurenine and increased serotonin concentrations. This creates a mechanism in which
depressive behavior could be influenced via a two-pronged approach that begins with gut
microbiota. It is uncertain whether or not this mechanism functions in the human body as
studies have only been in mice.

General Direction of Study: Proposing a Probiotic Intervention in Humans
I am proposing to study a probiotic intervention in humans, by measuring the effect
of probiotics (Lactobacillus reuteri) on metabolite concentrations. These metabolites are
involved in the kynurenine pathway, which is a pathway that has been associated with
depression in mice (16, 21, 22). The majority of studies in mice have focused on total
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circulating tryptophan levels with less attention given to the dynamics of tryptophan
metabolism along the kynurenine pathway (16, 30). This study would look directly at
tryptophan metabolism along the kynurenine pathway by measuring metabolites downstream
of this pathway.
Aims
An aim of this study is to assess whether L. reuteri inhibits IDO expression in
humans, as seen in Valladares et al.’s mouse study, and if this probiotic feeding
influences tryptophan metabolism down the kynurenine pathway. Another goal is to
further understand the impact of L reuteri in the human body and its role in
depression.
Predictions
I predict that if individuals are fed L. reuteri for 30 days, then tryptophan metabolism
along the kynurenine pathway will be affected. More specifically, I predict that in
group 2, patients taking the L. reuteri supplement, there will be lower levels of IDO
expression, kynurenic acid, quinolinic acid, kynurenine, c reactive protein and IFNγ,
and higher levels of tryptophan, serotonin, interleukins (IL-4 and IL-10) and H2O2.
Thus, I predict that there will be less tryptophan metabolism down the kynurenine
pathway in group 2 compared to group 1 (control/placebo group). In addition, I
predict there will be higher levels of serotonin and lower levels of kynurenine per
each patient in group 2, which will consequently impact their mood given previous
findings in this pathway, thus, there will be lower levels of depression according to
the PHQ-9 among group 2. I predict that at day 30, the microbiota community
structure of individuals in group 2 will be substantially different, with a higher
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concentration of Lactobacillus in the gut in comparison to group 1. I also predict that
microbiota community structure will be indistinguishable between both groups at day
0 and group 1 on day 30.

Methods

Figure 4. Clinical study timeline
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I will collect urine, feces and blood samples at the beginning of my study from all
patients. I would partner with a gastroenterologist who is performing colonoscopies to gather
my sample for this study. I would recruit patients of the gastroenterologist who were already
scheduled for colonoscopies, and who were willing to participate and donate samples. This
sample would hopefully be at least 60 people, and then patients would be randomized into
two separate groups. Ideally each group of 30 is a random sample of people representative of
the broader population, yet with a similar makeup across the 2 groups. I would hope to have
a sample size of at least 60 people total, which is based on previous mouse and human
studies (11, 21, 22). Most mouse studies have a sample size of 20-30 mice total, and most
human studies have a sample size of 60-70 humans total. Thus, I hope to get at least 60
people enrolled in my study, which would then allow 30 people at the minimum in each
group.
Group 1: Roughly 30 people who will be taking a placebo pill = control group
Colonoscopy= Day 30
Group 2: Roughly 30 people who will be taking the L. reuteri probiotic
Colonoscopy= Day 30
I chose to administer a probiotic to group 2 of solely L. reuteri, as it has been shown
to directly inhibit IDO1 in the kynurenine pathway in mice (22). In addition, L. reuteri is a
species that colonizes several vertebrate hosts, including rodents and humans, and was shown
to improve depression and anxiety-like behaviors, including the forced swim test in mice (10,
22, 31). 2 x 109 CFU/mL of L. reuteri will be given to group 2 in oral capsule form for 30
days. Amount of CFUs given per milliliter was determined based on previous studies in mice
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and humans (11, 22). L. reuteri would be obtained from ATCC (23272) (22), and then
encapsulated for oral consumption. Group 1, the control group, will be given a placebo of
identical taste and appearance as the probiotic, for 30 days (11). All patients will be advised
to take their oral pill during or just after breakfast, and will be reminded through a daily text
message. Study compliance would be assessed by counting the number of pills returned by
participants at the end of the study (11).
Samples would be collected again at 30 days. These samples would be urine, feces
and blood samples again from both groups, and I would collect colonic biopsies from their
colonoscopies after taking the other samples (Figure 4). I would then quantify metabolite
concentrations using the methods described below.
Blood Serum Sample Analysis
All blood samples would be collected from the patient’s vein in their arm. For
analyzing whole blood, blood would be collected into glass Vacutainer Tubes containing
disodium EDTA (32). Platelets would be counted with a Model S plus 4 Coulter Counter and
then whole blood would be apportioned into 1 mL aliquots, stored at -20˚C and would be
analyzed within 1 week after collection (32). For analyzing serum, blood would be collected
into a covered test tube that is prepped for serum analysis. This sample would be centrifuged
at 2000 g for 10 minutes at 4˚C, and apportioned into 0.5 mL aliquots and stored at -80˚C
(21) until ready to be analyzed. These individual aliquots then allow for various serum
sample analyses later on, and provide several aliquots to pull from, especially if a different
analysis is desired much farther in the future.
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To measure kynurenine, tryptophan and kynurenic acid levels in blood samples, I
would use reverse-phase high performance liquid chromatography (HPLC), as described
previously (30). In short, this involves using blood serum and a HPLC procedure with
ultraviolet and fluorimetric detection to separate and quantify tryptophan, kynurenine and
kynurenic acid. It has the ability to measure other kynurenine metabolites, but has not been
expanded to measure quinolinic acid yet (30). Because Badawy’s method is unable to
measure quinolinic acid, I would use a gas chromatography/mass spectrometry (GC/MS)
assay to measure quinolinic acid in whole blood as described previously by Heyes and
Markey (33). This experiment used whole blood samples, rather than serum samples, as it
was found to be more effective in the GS/MS assay. In short, this GS/MS assay includes
sample analysis through Finnigan 3200 chemical ionization quadrupole mass filter with
Extrel electronics and a Teknivent data system 1050, and quinolinic acid is analyzed by
selected ion monitoring (33). In addition, I would use HPLC with amperometric detection for
determination of serotonin in whole blood, as described previously (32). This experiment was
also found to be most effective using whole blood samples, rather than serum samples. In
short, this HPLC includes a Model 510 HPLC pump, a Model SIL 9A autosampler from
Shimadzu Analytical Division and a Model 460 amperometric detector equipped with a
glassy carbon electrode maintained at a potential of +0.6V (32). In addition, I would measure
inflammation through c reactive protein levels in blood serum, which can be done using a
Human C Reactive Protein ELISA Kit by following the manufacturer’s instructions (Thermo
Fischer KHA0031, Walthan, MA).
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Urine Sample Analysis
I would measure kynurenic acid and tryptophan levels in urine samples using reversephase HPLC as described previously by John B. Tarr (34). In short, this method includes a
Model 6000A pumping system, Model 440 ultraviolet absorbance detector set at 254 nm, and
Model R40l differential refractometer, and all chromatograms are obtained at ambient
temperature (around 20°C) (34). Tarr’s method, however, was unable to measure quinolinic
acid levels in urine, because the conditions used in Tarr’s analysis gave too broad of an
elution for quinolinic acid for it to be of analytical use. So I would measure quinolinic acid
levels through a process described by McDaniel et al. (35). This process involves bringing
urine samples to pH 1.4 with hydrochloric acid and then adding 3 grams of Norit-A to each
50mL aliquot of urine. Norit-A is an activated carbon that is a great adsorbent and is
commonly used in purification processes and the removal of dyes (36). This addition of
Norit-A creates a charcoal suspension that is then filtered out and ammonium hydroxide is
added. The ammonium hydroxide filtrate is evaporated to dryness over a 50°C water bath,
and this dry residue is then taken up in 5 mL of glacial acetic acid, and heated at 105°C.
After cooling, 1 mL of the acetic acid is then brought to pH 7.3 by the addition of sodium
hydroxide. 3 mL of 1M Tris-HCl is added to the neutralized acetic acid solution and the final
volume is brought to 10 mL with distilled water. 1 mL of this solution is then placed in a tube
with ethanol, cyanogen bromide and o-toluidine. Absorbance of this solution is compared to
that of the blank at 450nm using a Beckman DU or Zeiss spectrophotometer (35). Ultimately,
this protocol achieves the desired chemical reaction, the decarboxylation of quinolinic acid to
nicotinic acid, which is necessary to determine the quinolinic acid concentration in urine
(35). Urinary serotonin would be purified by two successive cationic and anionic extraction
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steps, then serotonin levels would be measured under the same chromatographic conditions
as used for quantifying blood serum levels, which was described previously by Pussard et al.
(32). All urine samples would be collected and then frozen at −20 °C and transferred to lower
storage temperatures (−80 °C) within one week (37). Total protein concentration in each
patient’s urine sample would be measured using a Bradford assay (Bio-Rad Laboratories,
Hercules, CA) following the manufacturer’s instructions. Each patient’s tryptophan
measurement would then be compared to their total protein concentration in order to obtain
the amount of tryptophan per microgram of protein in the urine. This would be done with
each measurement from the urine, so kynurenic acid, quinolinic acid and serotonin as well.
This ratio then allows for a more accurate comparison across patients, as it accounts for
confounding variables, for example if someone just drank alcohol, their protein levels would
be much higher than another patient.
Fecal Matter Sample Analysis
I would assess bacterial community structure by first performing 16S rRNA
sequencing on genomic DNA isolated from fecal samples. Whole genomic DNA would be
isolated via phenol-chloroform extraction as described by Marin et al. (22). For 16S rRNA
sequencing, the V3-V4 region of the 16S rRNA gene would be amplified using polymerase
chain reaction (PCR) for 25 cycles using specific primers (forward 5’TCGTCGGCAGCGTCAGATGTGTA TAAGAGACAGCCTACGGGNGGCWGCAG- 3’
and reverse 5’- GTCTCGTGGGCTCGGAGATGTGTA
TAAGAGACAGGACTACHVGGGTATCTAATCC-3’) as per the Illumina library
preparation guide as explained in the supplemental figures by Marin et al. (22). DNA
sequences will be processed in a data curation pipeline, such as mothur (38), that will remove
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all sequences with indicators of low sequence confidence, such as those with a read quality
score of under 25, sequences that contain ambiguous characters or contain more than four
mismatches to the reverse primer sequence, or sequences that are less than 200 nucleotides or
greater than 600 nucleotides (39). The sequences are then clustered into operational
taxonomic units (OTUs), which are based on sequence identity (%ID), and various thresholds
of sequence identity are used to represent different taxonomic levels (e.g., 97% ID for
species, 95% for genera) (40). Using each patient’s compiled list of OTUs (from fecal
samples) and their relative abundance (assigned a value between 0 and 1), a similarity matrix
would be created to further reduce the complexities of each patient’s microbiota community
structure and facilitate statistical analysis. I would then use principal coordinates analysis
(PCoA) to visualize similarities and dissimilarities of data across patients (40).
I would measure H2O2 (reactive oxygen species, ROS) in feces using the Amplex Red
hydrogen peroxide/peroxidase assay kit (Thermo Fischer) according to the manufacturer’s
protocol. For ROS production by individual L. reuteri species, fecal L. reuteri would be
cultured, and individual colonies would be selected and dissociated as described by Marin et
al. (22), and then quantified using the Amplex Red hydrogen peroxide/peroxidase assay kit
as described above.
I would prep all fecal samples by collecting the fresh sample, weighing it, and then
resuspending part of it in sterile phosphate-buffered saline (PBS) (22). After brief
sedimentation of insoluble particles, part of this bacterial slurry would be incubated at 37˚C
for 30 minutes (22). After bacterial culture centrifugation, the supernatant would be reacted
with the Amplex Red assay kit. Otherwise, fecal matter samples will be stored at -80˚C for
microbiota composition assessment.
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Colonic Biopsy Analysis
Each patient will have a colonoscopy at 30 days, and during the colonoscopy, the
gastroenterologist will take a tissue sample from the colon. Half of this tissue sample will
then be preserved in RNAlater, which is a tissue storage reagent that stabilizes and protects
cellular RNA, in order to analyze IDO expression (21). The other half of this tissue sample
will be homogenized using a Tissue Master 125 (Omni International, Kennesaw, GA) with
protease inhibitors (Sigma-Aldrich, St. Louis, MO) in order to analyze levels of
inflammatory cytokines and chemokines (21). All samples will be stored at -80˚C until
processing. For RNA quantification, frozen tissues would be homogenized by bead beating in
RNA TRI Reagent (Life Technologies, Carlsbad, CA) and RNA would be extracted
according to manufacturer’s protocol (22). IDO expression would then be measured using
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), as described by
Valladares et al. (21). In short, the desired RNA template would be copied into a
complementary DNA (cDNA) using a retroviral reverse transcriptase, and then this cDNA is
amplified exponentially by PCR. cDNA would be synthesized using iScript cDNA synthesis
kit (Bio-Rad Laboratories), by following the manufacturer’s instructions (21). qRT-PCR
would then be performed using an iCycler detection system (Bio-Rad Laboratories) using
200nM concentrations of each primer, and following the manufacturer’s instructions (21).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) would be used as an internal control.
Primers used would be: human IDO, forward 5’-GGTCATGGAGATGTCCGTAA-3’ and
reverse 5’-ACCAATAGAGAGACCAGGAAGAA-3’, and human GAPDH forward 5’ACCACAGTCCATGCCATCAC-3’ and reverse 5’-TCCACCACCCTGTTGCTGTA-3’
(21). Reaction conditions would be the same as those used by Valladares et al. Data from the
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iCycler detection system (Bio-Rad Laboratories) would be analyzed with iCycler software
using the cycle threshold values (Ct) method of relative transcript analysis (2-∆∆Ct) to
determine the relative quantification (21). For determining levels of inflammatory cytokines
and chemokines [IFNγ, interleukin (IL-4 and IL-10)] in tissue samples, I would use the
homogenized tissue sample with protease inhibitors and a tissue lysate enzyme-linked
immunosorbent assay (ELISA). I would specifically use the Human Inflammatory Cytokines
Multi-Analyte ELISArray Kit from QIAGEN (Hilden, Germany), which is a kit that was
similarly used by Valladares et al. in their mouse study (21). Total protein concentration in
each patient’s colonic biopsy sample would be measured using a Bradford assay (Bio-Rad
Laboratories) following the manufacturer’s instructions, as described above with urine
samples. Each patient’s IFNγ, IL-10 and IL-4 measurements would then be compared to their
total protein concentration in order to obtain the amount of IFNγ, IL-10 or IL-4 per
microgram of protein in the tissue sample.
Questionnaire
I would use the Patient Health Questionnaire (PHQ-9) (41) to test for depression-like
symptoms pre and post treatment. This questionnaire allows for a quantitative measurement
of depression. I would also propose a questionnaire to test for confounding variables, such as
smoking, drinking, diet, stress levels, general physical activity levels, and any prescription
drugs each patient is taking. This questionnaire would be given to patients on days 0 and 30
to assess for confounding variables but also to test whether there was any variance or change
in 30 days. I plan on first using this questionnaire to assess whether someone needs to be
removed from the study. The criteria for a participant’s removal are: daily consumption of a
significant amount of pre- and probiotics, daily consumption of five or more alcoholic

24
beverages, use of illegal drugs, or any indication that they will not reliably take their given
pill for thirty days. Any other factor indicating that a participant would skew results is also
grounds for removal from the study. I would then adjust for the remaining confounding
variables through stratification. Stratification is a method in which the data set is broken into
a number of subsets, called strata, corresponding to the number of potential confounders
(e.g., smoking and stress levels) (42). The association between treatment (group 1 or 2) and
time (day 0 or 30) with metabolite concentration is evaluated within each stratum of the
confounder, for each metabolite (43). This then calculates a stratum-specific estimate, and
makes it evident whether a factor introduces confounding in the analysis (42). The MantelHaenszel method can then be used to provide an adjusted result according to strata, by
calculating a weighted average of them (44). This calculated adjusted result would then be
reported and discussed as a limitation of the study.

Statistical Analysis
For each group, I would perform a t-test between day 0 and day 30 for every
metabolite (between column 1 and 2 in Table 1 below), not including microbiota composition
and findings from the colonic biopsy. All metabolite measurements across patients in each
group would be averaged and then statistically analyzed. I would perform a t-test for average
findings for each metabolite between groups 1 and 2 on day 0 and on day 30. Figure 5
describes the general overview for which t-tests I would perform.
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Table 1. Samples and average measurements from each group.
Average Metabolite Level

Average Metabolite Level

on Day 0

on Day 30

Serotonin

Serotonin

Kynurenine

Kynurenine

Tryptophan

Tryptophan

Kynurenic acid

Kynurenic acid

C reactive protein

C reactive protein

Tryptophan

Tryptophan

Kynurenic acid

Kynurenic acid

Quinolinic acid

Quinolinic acid

Serotonin

Serotonin

Microbiota composition

Microbiota composition

H2O2

H2O2

N/A

IDO expression

N/A

IFNγ

N/A

Interleukins

Sample

Blood

Urine

Feces

Colonic Biopsy

•

IL-4

•

IL-10

Patient Health Questionnaire

Patient Health Questionnaire

(PHQ-9)

(PHQ-9)

Confounding variables

Confounding variables

questionnaire

questionnaire

Questionnaire

Figure 5 shows expected t-test findings between the groups for each metabolite if my
hypotheses were supported (see expected results section for further analysis). For example,
Figure 5 shows average measurements for kynurenine across groups 1 and 2.
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Figure 5. Statistical analysis of average findings for each metabolite. Also, the expected ttest findings for each metabolite between groups 1 and 2 if my hypotheses were supported.
A permutational multivariate analysis of variance (PERMANOVA) would be used to
assess microbiota composition across individuals, which will compare the similarity scores
given for each individual in the similarity matrix (as described in fecal matter sample
analysis above) (45). PERMANOVA will indicate if microbiota community structure is
significantly different between groups 1 and 2. More specifically, it will provide further
information on whether treatment or time affects the p-value, and which is more significant.
In addition, I would use principal coordinates analysis (PCoA) to visualize dissimilarities
between bacterial communities across patients. I would be able to see if there is a difference
between individuals on day 30 after taking L. reuteri and individuals on day 30 after taking
the placebo. Additionally, I will be able to use the PCoA ordination to discover the species
and factors that strongly correlate to the patterns seen across treatment groups by using key
indicator species analysis (46). Using key indicator species analysis, it is possible to identify
which treatment (group 1 vs. 2), time (day 0 vs. 30), and metabolite is driving this shift in
microbiota.
Ultimately the findings from the colonic biopsies would be additional support to the
other samples (feces, urine & blood), as they are more difficult to collect, so there will likely
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be a higher failure rate. I would plan on correlating findings of IDO expression, IFNγ, IL-10
and IL-4, with findings from the other samples for each individual. This would be done
through calculating the average level of IDO expression, IFNγ, IL-10 and IL-4 across groups,
and then performing a t-test between group 1 and 2 for each finding to test for statistical
significance.

Expected Results
If my hypotheses were supported, I expect certain levels of metabolites to be higher
than others, and some t-tests to result in p-values that are significant and others with p-values
that are non-significant. I expect a significant difference for every metabolite between groups
1 and 2 on day 30 (Figure 5 in methods). In addition, I expect a significant difference within
group 2 on day 0 vs. 30 for every metabolite (Figure 5). However, I expect no significant
difference between groups on day 0, and within group 1 between day 0 and 30 (Figure 5).
Table 2 shows the expected average metabolite level in group 2 day 30, where I expect there
to be a statistically significant difference when compared to both groups at day 0, and when
compared to group 1 at day 30. Overall, I suspect metabolite levels in group 2 day 30 to be
substantially different (Table 2). I chose to measure some metabolites in multiple samples
throughout my study, so for these, serotonin, kynurenine, tryptophan and kynurenic acid, I
have chosen to label them with varying degrees of expected increase or decrease in findings.
+ indicates an increase, and – indicates a decrease, in metabolite level as compared to group
1 and 2 day 0, and as compared to group 1 day 30 (Table 2). ++ indicates an even greater
increase, whereas - - indicates an even greater decrease (Table 2).
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Table 2. Expected average metabolite concentration level in group 2 on day 30 as compared
to group 2 on day 0 and group 1 on day 0 and 30.
Metabolite

Expected Average Change in
Metabolite Concentration (+/-)

Serotonin from blood sample

+

Serotonin from urine sample

++

Kynurenine from blood sample

-

Kynurenine from urine sample

--

Tryptophan from blood sample

+

Tryptophan from urine sample

++

Kynurenic acid from blood sample

-

Kynurenic acid from urine sample

--

C reactive protein

-

Quinolinic acid

-

H2O2

++

IDO expression

-

IFNγ

-

Interleukins
•

IL-4

+

•

IL-10

+

Patient Health Questionnaire

-

(PHQ-9) numerical results

In general, I expect kynurenine pathway metabolite levels to be higher in urine than
in blood (47). A critical aspect of Table 2 is that I expect lower IDO expression and lower
levels of kynurenine, and higher tryptophan and serotonin levels in the group of patients that
have been taking L. reuteri as compared to the placebo group (21, 22). This would imply that
the L. reuteri feeding was effective in influencing tryptophan metabolism down the
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kynurenine pathway, and a potential reason for this is that L. reuteri produces H2O2, which
inhibits IDO and consequently results in higher levels of tryptophan and serotonin, and lower
levels of kynurenine.
I expect to see a reduction in depression attributable to a certain treatment. My
expected results consistent with this would be from the PHQ-9 responses. I expect to see
lower levels of depression in group 2 day 30 as indicated through the numerical value from
the questionnaire. I would then correlate this finding to serotonin and kynurenine levels. I
would correlate these findings using a linear regression to obtain slope, r2 and r, the Pearson
product-moment correlation coefficient. I would then use Vassar stats (http://vassarstats.net/)
to test for the significance of the Pearson product-moment correlation coefficient. I expect to
see significance between low questionnaire values and low levels of kynurenine, and low
questionnaire values with high levels of serotonin.
I expect to see a significant change in community structure due to probiotic feeding.
My expected results consistent with this would be a significant shift in community structure
on day 30 for group 2, as compared to group 2 day 0, and group 1 day 0 and 30. This
expected shift is depicted in Figure 6. I would expect to see more L. reuteri present in the
stool samples of individuals from group 2 on day 30, than individuals from group 1 on day 0
and 30, and from group 2 on day 0.
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Figure 6. Expected experimental ordination of microbial communities for both treatments on
day 0 and day 30 (n=30). Community structure is expected to shift in group 2 on day 30 after
probiotic consumption.

Discussion
If my hypotheses were supported, then this would indicate that the mouse findings
from Valladares et al., and Marin et al. could be translated to humans. This study would give
a greater glimpse into a mechanism behind this gut-brain axis in humans. If findings support
my hypotheses, then the kynurenine pathway proves to be a significant pathway in
understanding how our gut microbes influence depression. In addition, L. reuteri would
prove to be influential in this axis and play a role in depression. This could broaden the view
on probiotics as one that is not just focused on the gut, but also on the brain.
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This study contributes measurements of specific markers using several samples, such
as H2O2 in feces or kynurenine levels in urine or blood, which could be valuable for other
purposes, such as prognosis or monitoring changes throughout drug or probiotic intervention.
The results from this study would be valuable in establishing a mechanistic connection
between the gut and the brain. Additionally, the kynurenine pathway could serve as a target
for drugs or other therapies in treating depression. This would especially be true if the link to
depression is supported through the PHQ-9 questionnaire responses, because this would open
the opportunity to view depression in an entirely different way than the current view in the
medical field and society. Antidepressants would no longer be the main way to ease
depression symptoms, and this pathway could serve as a way to truly cure and treat
depression. If gut microbes and tryptophan metabolism along the kynurenine pathway play
significant roles in depression, then the emphasis previously placed on the brain would
lessen. Depression would no longer be viewed as a chemical imbalance in the brain, but
instead an imbalance in gut microbiota.

Complicating Factors
This study contains a few complicating factors that are uncontrolled. First,
compliance with taking the probiotic treatment will be facilitated through counting pills
returned at the end of the study, but this could allow patients to throw out or keep pills in
order to make it seem like they took it every day, when they really did not. Another
important consideration in my study is the role of confounding variables on my results. I plan
on assessing for confounding variables through the questionnaire given at the beginning and
end of my study, however, these confounding variables could influence my data. For
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example, the diet of each patient will be not be controlled or restricted, meaning that the
occasional consumption of prebiotic and probiotic rich foods could influence metabolite
levels and PHQ-9 findings. It would be detrimental to my study if a patient in group 1
consumed prebiotic and probiotic rich foods, because their microbiota and metabolite levels
may look similar to a patient in group 2. Other variables such as physical activity and
moderate alcohol consumption could influence my data as well. Another influencing factor is
the level of depression among patients in group 1 and 2 on day 0. I plan to randomize my
sample into two groups, however, this does not account for people who are depressed. Major
depressive disorder (MDD) affects about 6.7% of the U.S. population, and is more prevalent
in women than in men (48). 6.7% of my 60-person sample size is 4 people, so I calculated
the binomial probability of my sample to contain 4 people with MDD. This resulted in the
mere chance probability of 20.21% for exactly 4 people in my study with MDD. In addition,
there is 42.27% probability of having 4 or fewer people with MDD, and 37.52% probability
of having 4 or more people in my study with MDD. I also calculated the binomial probability
of my sample to contain one person with MDD, because having only one person with MDD
in my study would most significantly impact my results, as one of the two groups would have
zero people with MDD. This binomial probability resulted in the mere chance probability of
6.7% for exactly 1 person in my study with MDD. In addition, there is 1.5% probability of
having 1 or fewer people with MDD, and 91.8% probability of having 1 or more people in
my study with MDD. Thus I would expect between 1-4 people in my study to have MDD, so
upon randomizing people into two groups, this randomization could potentially lead to an
uneven distribution of people with depression across the two groups, which would influence
my results, especially when looking at PHQ-9 outcomes and metabolite levels. Ultimately, I
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expect my sample to contain people with major depressive disorder, which is an important
factor that will not be controlled for. Finally, another important influencing factor is that
people coming in to get colonoscopies and regularly checking in with a gastroenterologist
may not be representative of the general population. This is because people who are coming
in to get colonoscopies are likely of a certain age, health status and socioeconomic status.
These patients have the money and time to access a gastroenterologist, and are typically
around 50 years old. Additionally, women are more likely than men to have a colonoscopy
(49), so there may not be an even split among males and females in my sample. If my sample
group is not representative of the general population, then my data can not necessarily be
extrapolated for broader medical purposes.

Future Directions
The gut-brain axis and its link to depression is an increasingly popular topic of study
and conversation. However, research on this link is limited, especially in humans. Most
studies are limited to manipulation of rodents, which makes it difficult to apply these
findings to humans, and consequently impact the medical field. My study proposes a
probiotic intervention in humans, with the hope of getting a greater glimpse into the role the
kynurenine pathway plays in humans and the link between gut microbes and depression.
There are many areas that future researchers could explore in order to learn about and utilize
this relationship further.
A future direction is to look further into the kynurenine pathway and probiotics in
younger populations, as my sample will primarily contain people over 50 years old. These
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studies would not need to be so comprehensive, and could instead analyze feces or urine
samples in different populations to look at tryptophan metabolism along the kynurenine
pathway. In addition, I anticipate that IDO expression may not be statistically significant
with a small group of people, thus if this proves to be true, then a future direction for this
study would be to add more people to obtain a greater sample size to analyze IDO expression
in order to see statistical significance. Probiotic feeding of a larger sample size is
recommended, and also to use other strains of bacteria besides L. reuteri for probiotic
consumption. There is a lot of uncertainty surrounding which genera or species of bacteria
are most beneficial in this axis’ link to depression, and what they specifically do that proves
to be beneficial. Future research must focus on deciphering which bacteria influence the
kynurenine pathway, and if a probiotic formulation of such bacteria can serve as a
therapeutic strategy for mood disorders.
To conclude, this study holds the potential to demonstrate that the kynurenine
pathway is a critical link between the gut microbiome and depression in humans.
Additionally, this study could find that a thirty-day L. reuteri probiotic intervention can
influence tryptophan metabolism down the kynurenine pathway to increase circulating levels
of serotonin and tryptophan in the body, and decrease levels of kynurenine, which all
contribute to decrease levels of depression in an individual. An emphasis on the microbiome
in the treatment of depression could drastically alter the use of antidepressants and work
towards curing depression, rather than simply alleviating symptoms.
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